Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SELECTED FINANCIAL STATEMENT - ASSETS

SELECTED FINANCIAL STATEMENT - ASSETS

6 Months Ended

Jun. 30, 2022

Balance Sheet Related Disclosures [Abstract]

SELECTED FINANCIAL STATEMENT - ASSETS

NOTE 4 — SELECTED FINANCIAL STATEMENT — ASSETS

Inventories consisted of the following (in thousands):

	June 30, 2022			December 31, 2021
Raw materials and components	$	1,441		$	1,439
Work-in-process		362			115
Finished goods		5,739			6,228
Inventory reserve		(4,408	)		(3,390	)
Total inventories, net	$	3,134		$	4,392

Prepaid expenses and other current assets consisted of the following (in thousands):

	June 30, 2022		December 31, 2021
Prepaid insurance	$	378	$	660
Prepaid expenses		435		326
Other current assets		422		394
Total prepaid expenses and other current assets	$	1,235	$	1,380

Property and equipment consisted of the following (in thousands):

	June 30, 2022			December 31, 2021
Equipment	$	358		$	342
Leasehold improvements		39			39
Furniture and fixtures		99			103
Construction-in-progress		—			57
Total property and equipment		496			541
Less: accumulated depreciation		(411	)		(394	)
Total property and equipment, net	$	85		$	147

During the three months ended June 30, 2022 and 2021, depreciation expense was approximately $10,000 and $12,000, respectively. During the six months ended June 30, 2022 and 2021, depreciation expense was approximately $21,000 and $23,000, respectively.